ESC Professional Premium Access

Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan

Congress Presentation

About the speaker

Doctor Alberto Giannoni

Sant'Anna School of Advanced Studies, Pisa (Italy)
1 presentation
0 follower

7 more presentations in this session

Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?

Speaker: Doctor G. Oliveira Campos (Coimbra, PT)

Thumbnail

Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Bielecka-Dabrowa (Lodz, PL)

Thumbnail

Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Hernandez (Storrs, US)

Thumbnail

Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)

Speaker: Assistant Professor K. Lee (Incheon, KR)

Thumbnail

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

Speaker: Doctor H. Schwende (Basel, CH)

Thumbnail

Access the full session

Heart failure pharmacotherapy - Sacubitril/valsartan

Speakers: Doctor A. Giannoni, Doctor G. Oliveira Campos, Professor A. Bielecka-Dabrowa, Professor A. Hernandez, Assistant Professor K. Lee...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk